India, June 29 -- SIRO Clintech is repositioning itself from a traditional CRO to a Lifecycle Evidence Partner. What specific gaps in the current pharmaceutical ecosystem prompted this transformation?

Dr Gautam Daftary- The traditional CRO model was built for a different era. Sponsors hired us to execute discrete projects: a Phase III trial here, a publication there, a PMS (post marketing surveillance ) programme after the product launch. We delivered each piece competently in isolation. What we watched unfold over two decades is that data and insights generated within one project rarely informed the next. A trial would close, the dataset would lock away, and a year later the same molecule would face a guideline body, a payor, or a presc...